Arsenic trioxide‑induced cell apoptosis and cell cycle arrest are potentiated by 1,25‑dihydroxyvitamin D3 in human leukemia K562 cells

Zhang,Ya-Li; Qiao,Shu-Kai; Guo,Xiao-Nan; Ren,Jin-Hai; Zhang,Jing-Nan

doi:10.3892/ol.2021.12770

Arsenic trioxide‑induced cell apoptosis and cell cycle arrest are potentiated by 1,25‑dihydroxyvitamin D3 in human leukemia K562 cells

Authors:
- Ya-Li Zhang
- Shu-Kai Qiao
- Xiao-Nan Guo
- Jin-Hai Ren
- Jing-Nan Zhang
View Affiliations

Affiliations: Department of General Practice, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China
Published online on: May 3, 2021 https://doi.org/10.3892/ol.2021.12770
Article Number: 509
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The interaction between 1,25‑dihydroxyvitamin [1,25(OH)2D3] and vitamin D receptor (VDR) plays a critical role in regulating cell proliferation and programmed cell death. The present study aimed to investigate the effects of 1,25(OH)2D3 in combination with arsenic trioxide (As₂O₃) on the proliferation and cell cycle of a K562 leukemia cell line. K562 cells were treated with 100 nM 1,25(OH)2D3, 2.5 µM As₂O₃, and 100 nM 1,25(OH)2D3 combined with 2.5 µM As₂O₃. Cell proliferation was evaluated by the 3‑(4,5‑dimethylthiazol‑2‑yl)‑5‑(3‑carboxymethoxyphenyl)‑2‑(4‑sulfophenyl)‑2H‑tetrazolium, inner salt/phenazine ethosulfate method. Cell cycle progression and apoptosis were detected by flow cytometry. The expression levels of genes associated with the cell cycle and apoptosis were analyzed by reverse transcription‑quantitative PCR and western blotting analyses. The present findings indicated that combined treatment of 1,25(OH)2D3 and As₂O₃ led to a significant increase in cytotoxicity, apoptotic cell death and G1 cell cycle arrest when compared to those treated with 1,25(OH)2D3 or As₂O₃ alone. The downregulation of the Bax/Bcl‑2 ratio and decreased survivin expression may be involved in combined treatment‑mediated apoptosis. G₀/G₁ cell cycle arrest induced by combined treatment was associated with the activation of p21 and p27. In addition, the increased expression of VDR was found to participate in the anticancer effect of combination treatment. The data suggested that the combination of 1, 25‑(OH)₂D₃ and As₂O₃ had clear synergistic effects on the inhibition of K562 cell proliferation, which could provide a novel therapeutic approach for the treatment of acute myeloid leukemia.

View Figures

View References

1	Christakos S, Dhawan P, Verstuyf A, Verlinden L and Carmeliet G: Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev. 96:365–408. 2016. View Article : Google Scholar : PubMed/NCBI
2	Umar M, Sastry KS and Chouchane AI: Role of vitamin D beyond the skeletal function: A review of the molecular and clinical studies. Int J Mol Sci. 19:16182018. View Article : Google Scholar : PubMed/NCBI
3	Krishnan AV and Feldman D: Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol. 51:311–336. 2011. View Article : Google Scholar : PubMed/NCBI
4	Grant WB and Boucher BJ: Randomized controlled trials of vitamin D and cancer incidence: A modeling study. PLoS One. 12:e01764482017. View Article : Google Scholar : PubMed/NCBI
5	Bandera Merchan B, Morcillo S, Martin-Nuñez G, Tinahones FJ and Macías-González M: The role of vitamin D and VDR in carcinogenesis: Through epidemiology and basic sciences. J Steroid Biochem Mol Biol. 167:203–218. 2017. View Article : Google Scholar : PubMed/NCBI
6	Picotto G, Liaudat AC, Bohl L and Tolosa de Talamoni N: Molecular aspects of vitamin D anticancer activity. Cancer Invest. 30:604–614. 2012. View Article : Google Scholar : PubMed/NCBI
7	Díaz L, Díaz-Muñoz M, García-Gaytán AC and Méndez I: Mechanistic effects of calcitriol in cancer biology. Nutrients. 7:5020–5050. 2015. View Article : Google Scholar
8	Campbell MJ and Trump DL: Vitamin D receptor signaling and cancer. Endocrinol Metab Clin North Am. 46:1009–1038. 2017. View Article : Google Scholar : PubMed/NCBI
9	Kulling PM, Olson KC, Olson TL, Feith DJ and Loughran TP Jr: Vitamin D in hematological disorders and malignancies. Eur J Haematol. 98:187–197. 2017. View Article : Google Scholar : PubMed/NCBI
10	Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S and Cortes J: Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia. Cancer. 97:2218–2224. 2003. View Article : Google Scholar : PubMed/NCBI
11	Hoonjan M, Jadhav V and Bhatt P: Arsenic trioxide: Insights into its evolution to an anticancer agent. J Biol Inorg Chem. 23:313–329. 2018. View Article : Google Scholar : PubMed/NCBI
12	Abudoureyimu A and Muhemaitibake A: Arsenic trioxide regulates gastric cancer cell apoptosis by mediating cAMP. Eur Rev Med Pharmacol Sci. 21:612–617. 2017.PubMed/NCBI
13	Sadaf N, Kumar N, Ali M, Ali V, Bimal S and Haque R: Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells. Life Sci. 205:9–17. 2018. View Article : Google Scholar : PubMed/NCBI
14	Woo SH, Park IC, Park MJ, Lee HC, Lee SJ, Chun YJ, Lee SH, Hong SI and Rhee CH: Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol. 21:57–63. 2002.PubMed/NCBI
15	Kizildag S, Ates H and Kizildag S: Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21. Ann Hematol. 89:1–7. 2010. View Article : Google Scholar : PubMed/NCBI
16	Bae JY, Kim JW and Kim I: Low-dose 1,25-dihydroxyvitamin D(3) combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis. Oncol Rep. 30:485–491. 2013. View Article : Google Scholar : PubMed/NCBI
17	Pozarowski P and Darzynkiewicz Z: Analysis of cell cycle by flow cytometry. Methods Mol Biol. 281:301–311. 2004.PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Deeb KK, Trump DL and Johnson CS: Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer. 7:684–700. 2007. View Article : Google Scholar : PubMed/NCBI
20	Krishnan AV, Trump DL, Johnson CS and Feldman D: The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am. 39:401–418. 2010. View Article : Google Scholar : PubMed/NCBI
21	Peery RC, Liu JY and Zhang JT: Targeting survivin for therapeutic discovery: Past, present, and future promises. Drug Discov Today. 22:1466–1477. 2017. View Article : Google Scholar : PubMed/NCBI
22	Mobahat M, Narendran A and Riabowol K: Survivin as a preferential target for cancer therapy. Int J Mol Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
23	Friedrichs B, Siegel S, Andersen MH, Schmitz N and Zeis M: Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies. Leuk Lymphoma. 47:978–985. 2006. View Article : Google Scholar : PubMed/NCBI
24	Li N, Guan X, Li F, Li X and Chen Y: Vorinostat enhances chemosensitivity to arsenic trioxide in K562 cell line. Peer J. 3:e9622015. View Article : Google Scholar : PubMed/NCBI